Actively Recruiting

Phase 2
Age: 21Years +
All Genders
NCT06806930

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

Led by George Washington University · Updated on 2026-03-03

90

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to determine how the duration of hormone blocking (endocrine) therapy given prior to surgery (called "neoadjuvant" treatment) affects breast cancer. The main questions the trial aims is answer are: 1. How breast cancer responds to endocrine therapy given prior to surgery? 2. To predict tumor pre-operative endocrine prognostic index (PEPI) score for subjects enrolled in cohort B or C Participants with early-stage breast cancer (Stage I-III) who are eligible for Neoadjuvant Endocrine Therapy (NET) will be enrolled in the study. Participants will: * receive endocrine therapy as part of regular care for breast cancer * consent to samples of blood and tissue evaluation to determine how endocrine therapy effects the tumor * participate in this research anywhere from 2 weeks to 1 year, depending on duration of endocrine therapy and when surgery will be performed

CONDITIONS

Official Title

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

Who Can Participate

Age: 21Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to understand the investigational nature of the study and all relevant details
  • Able to provide written informed consent
  • Confirmed diagnosis of invasive breast carcinoma by biopsy
  • Clinical stage 1 to 3 breast cancer
  • Candidate for surgical removal of tumor
  • Estrogen receptor positive with >10% stained cells on recent biopsy
  • HER2 negative or HER2 low breast cancer, not eligible for HER2-targeted therapy
  • Able to take oral medications
  • Willing and able to follow scheduled visits, treatment, and research follow-up
  • Age 21 years or older
Not Eligible

You will not qualify if you...

  • Unable to comply with taking neoadjuvant endocrine therapy (NET)
  • Unable to follow study procedures

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

George Washington-Medical Faculty Associates

Washington D.C., District of Columbia, United States, 20037

Actively Recruiting

Loading map...

Research Team

P

Pavani Chalasani, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here